Company intelligence / Profile preview

Vitalis Pharmaceuticals

New York City, New York, United Statesvitalispharma.com ↗

Ownership: Private
Development stage: NDA

Overview

Vitalis Pharmaceuticals is developing proprietary IP-protected forms of aspirin and combination therapies aimed at improving patient outcomes by overcoming limitations of existing drugs. Their lead programs include a novel oral ketamine/aspirin formulation for acute musculoskeletal pain and VTS‑72, designed to reduce fumarate-induced flushing in multiple sclerosis patients. The company has received orphan drug designation for its combination therapies targeting MS-related side effects.

Therapeutic areas: RheumatologyNeurology
Modalities: Small molecules (notably proprietary forms of aspirin and combinations with other small molecules such as ketamine and fumarates)
Industry: Biotech

Drug pipeline

1 asset

VTS-63

Unknown

Beyond the preview

Go deeper on Vitalis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitalis Pharmaceuticals.

Explore the full profile